Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
J. Taieb
(1)
,
K. Le Malicot
(2, 3)
,
R. Balogoum
(4, 5, 6)
,
J. Tabernero
(7)
,
E. Mini
(8)
,
G. Folprecht
(9)
,
L. van Laethem
(10)
,
J-F. Emile
(11)
,
C. Mulot
(6)
,
S. Fratté
(12)
,
C-B. Levaché
(13)
,
L. Saban-Roche
(14)
,
J. Thaler
(15)
,
L. Nørgård Petersen
(16)
,
E. Sanchez
(17)
,
J. Bridgewater
,
G. Perkins
(4, 5, 6)
,
Come Lepage
(18, 19)
,
A. Zaanan
(1)
,
P. Laurent-Puig
(4, 5, 6)
1
Service de gastroenterologie [CHU HEGP]
2 FFCD - Fédération Francophone de Cancérologie Digestive
3 DIM - Service Biostatistiques et Informatique Médicale (CHU de Dijon)
4 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
5 HEGP - Hôpital Européen Georges Pompidou [APHP]
6 MEPPOT - U1147 - Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique
7 Vall d'Hebron University Hospital [Barcelona]
8 Dpt of Internal Medicine, Section of Immunoallergology and Respiratory [Florence] Diseases
9 Carl Gustav Carus University Hospital
10 Département de médecine interne [hôpital Erasme]
11 Service de pathologie [CHU Ambroise Paré]
12 CH Belfort-Montbéliard
13 Polyclinique Francheville
14 Institut de Cancérologie de la Loire Lucien Neuwirth
15 Klinikum Wels Grieskirchen
16 Rigshospitalet [Copenhagen]
17 IPO Porto - Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto
18 Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon)
19 LNC - Lipides - Nutrition - Cancer (U866)
2 FFCD - Fédération Francophone de Cancérologie Digestive
3 DIM - Service Biostatistiques et Informatique Médicale (CHU de Dijon)
4 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
5 HEGP - Hôpital Européen Georges Pompidou [APHP]
6 MEPPOT - U1147 - Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique
7 Vall d'Hebron University Hospital [Barcelona]
8 Dpt of Internal Medicine, Section of Immunoallergology and Respiratory [Florence] Diseases
9 Carl Gustav Carus University Hospital
10 Département de médecine interne [hôpital Erasme]
11 Service de pathologie [CHU Ambroise Paré]
12 CH Belfort-Montbéliard
13 Polyclinique Francheville
14 Institut de Cancérologie de la Loire Lucien Neuwirth
15 Klinikum Wels Grieskirchen
16 Rigshospitalet [Copenhagen]
17 IPO Porto - Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto
18 Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon)
19 LNC - Lipides - Nutrition - Cancer (U866)
Résumé
Background: RAS mutations have been shown to confer resistance to anti-EGFR treatment. We assessed here the results of the PETACC8 trial (Cetuximab + FOLFOX vs FOLFOX) in full wild type (WT) patients (pts) (RAS & BRAF). The prognostic impact of individual rare RAS and BRAF mutations has been tested.
Methods: Exons 2, 3 and 4 of KRAS and NRAS as well as BRAF exon 11 and 15 have been sequenced, using the ampliseq colon lung cancer panel V2, among the pts who have signed informed consent for translational research. The impact of cetuximab on Time To Recurrence (TTR), Disease Free Survival (DFS) and Overall Survival (OS), has been investigated in pts RAS WT, RAS & BRAF double WT tumors and in pts with rare...